How Personalized Is Multiple Myeloma Treatment and How Is That Changing? Introducing the Individual Risk Model for Myeloma

Event Description
As new targets and therapies are being discovered, the landscape of Multiple Myeloma treatment options is quickly evolving. How personalized are current treatment options, and how is that changing? Dr. Benjamin Diamond will join us to answer that question and give us an overview of IRMMa (Individual Risk Model for Myeloma) and it's implications for the future.
Event Highlights
Precision Medicine in Multiple Myeloma
Challenges in Treating High-Risk and Relapsed Multiple Myeloma
Toxicity and Precision in Immunotherapy
The Role of Genomics in Treatment and Personalization
Questions & Answers
Schedule & Agenda

Cynthia introduces the agenda of the event and featured speaker Dr. Benjamin Diamond

Cynthia introduces the agenda of the event and featured speaker Dr. Benjamin Diamond

Dr. Diamond talks about the landscape of Multiple Myeloma treatment

Dr. Diamond talks about the landscape of Multiple Myeloma treatment
Type your questions in the chat and we will answer them!
Type your questions in the chat and we will answer them!
Speakers & Moderators

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.

Dr. Diamond is a hematologist/oncologist who specializes in the treatment of plasma cell disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow, and is now an Assistant Professor at Sylvester Comprehensive Cancer Center is a member of the Myeloma Genomics Laboratory participating in translational research. His research interests include utilization of minimal residual disease (MRD)-guided approaches to clinical decision-making, maintenance therapy, and the genomics of multiple myeloma and secondary malignancies that occur in patients treated for multiple myeloma.
Join the Conversation
This event is part of the Disease Progression and Relapsed/Refractory group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org







Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.